8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 18, 2006)

Filed April 18, 2006For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on April 18, 2006, to report its first-quarter financial results for the period ended April 2, 2006. The filing primarily serves to attach a press release and supplementary financial data detailing the company's sales and earnings for the quarter. Investors would look to this report for an update on JNJ's financial performance in early 2006, as it provides the official announcement of key revenue and profit figures from the company itself. While the 8-K itself is a procedural filing, the attached press release and supplementary data (Exhibits 99.15 and 99.20) are the critical components for investors. These documents would contain details on the company's top-line sales growth across its various segments (Pharmaceuticals, Medical Devices & Diagnostics, and Consumer Health) and bottom-line earnings per share. Investors would analyze these figures to assess the company's ability to meet market expectations, identify trends, and understand the drivers of its financial results during the first quarter of 2006.

Key Highlights

  • 1Johnson & Johnson reported its first-quarter 2006 sales and earnings on April 18, 2006.
  • 2The 8-K filing officially disseminates the company's Q1 2006 financial results.
  • 3Key financial information is provided via an attached press release (Exhibit 99.15).
  • 4Unaudited comparative supplementary sales data and condensed consolidated statements of earnings for Q1 2006 are included as an exhibit (Exhibit 99.20).
  • 5The filing indicates the reporting period ended on April 2, 2006.
  • 6Stephen J. Cosgrove, Chief Accounting Officer, signed the report on behalf of Johnson & Johnson.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and disseminate Johnson & Johnson's financial results for the first quarter ended April 2, 2006, including sales and earnings, through an attached press release and supplementary financial data.

The detailed financial results, including sales and earnings for the first quarter of 2006, are located in the attached exhibits: Exhibit 99.15 (Press Release dated April 18, 2006) and Exhibit 99.20 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the first quarter).

These attachments typically contain key figures such as total sales, sales by business segment (Pharmaceuticals, Medical Devices & Diagnostics, Consumer Health), earnings per share, net income, and other relevant financial metrics for the reported quarter. They also provide comparative data from prior periods.

Stephen J. Cosgrove is identified as the Chief Accounting Officer of Johnson & Johnson. He is mentioned because he signed the 8-K report on behalf of the company, attesting to the accuracy of the information provided, as required by the Securities Exchange Act of 1934.